Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era

AIDS

Volumn 22, Issue 9, 2008, Pages 1019-1028

  Boffi El Amari, Emmanuelle ^a   Toutous Trellu, Laurence ^a   Gayet Ageron, Angèle ^a   Baumann, Michele ^b   Cathomas, Gieri ^b   Steffen, Ingrid ^c   Erb, Peter ^c   Mueller, Nicolas J ^d   Furrer, Hansjakob ^e   Cavassini, Matthias ^f   Vernazza, Pietro ^g   Hirsch, Hans H ^c   Bernasconi, Enos ^h   Hirschel, Bernard ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Liestal Institute of Pathology   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e UNIVERSITY OF BERN   (Switzerland)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^g St Gallen Hospital   (Switzerland)

^h Lugano Hospital   (Switzerland)

Author keywords

HIV; Human herpesvirus 8 DNA; Kaposi sarcoma; Predictive score; Risk factors

Indexed keywords

ACICLOVIR; ADEFOVIR; CIDOFOVIR; FOSCARNET; GANCICLOVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS DNA; VIRUS RNA;

ADULT; ARTICLE; CANCER STAGING; CD4 LYMPHOCYTE COUNT; CHEMOTHERAPY; CONCENTRATION (PARAMETERS); CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HAZARD RATIO; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK ASSESSMENT; SEROLOGY; SURVIVAL; TIME SERIES ANALYSIS; UNIVARIATE ANALYSIS; VIRUS DETECTION; VIRUS LOAD;

ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; FEMALE; HERPESVIRUS 8, HUMAN; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; RNA, VIRAL; SARCOMA, KAPOSI; SWITZERLAND; VIRAL LOAD;

EID: 44449170804     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282fc9c03     Document Type: Article

References (29)

1. Cathomas G. Kaposi's sarcoma-associated herpesvirus (KSHV)/human herpesvirus 8 (HHV-8) as a tumour virus. Herpes 2003; 10:72-77.
2. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266:1865-1869.
3. Mocroft A, Kirk O, Clumeck N, Gargalianos-Kakolyris P, Trocha H, Chentsova N, et al. The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003. Cancer 2004; 100:2644-2654.
4. Grulich AE, Yueming L, McDonald AM, Correll PK, Law MG, Kaldor JM. Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination antiretroviral therapy. AIDS 2001; 15:629-633.
5. Jones JL, Hanson DL, Dworkin MS, Jaffe HW, and the Adult/Adolescent Spectrum of Disease Project Group. Incidence and trends in Kaposi's sarcoma in the era of effective antiretroviral therapy. J Acquir Immune Defic Syndr 2000; 24:270-274.
6. Bourboulia D, Aldam D, Lagos D, Allen E, Williams I, Cornforth D, et al. Short- and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia. AIDS 2004; 18:485-493.
7. Sgadari C, Monini P, Barillari G, Ensoli B. Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth. Lancet Oncol 2003; 4:537-547.
8. Sgadari C, Barillari G, Toschi E, Carlei D, Bacigalupo I, Baccarini S, et al. HIV protease inhibitors are potent antiangiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 2002; 8:225-232.
9. Nasti G, Talamini R, Antinori A, Martellotta F, Jacchetti G, Chiodo F, et al. AIDS-related Kaposi's sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the HAART Era - the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals. J Clin Oncol 2003; 21:2876-2882.
10. Nasti G, Martellotta F, Berretta M, Mena M, Fasan M, Di Perri G, et al. Impact of highly active antiretroviral therapy on the presenting features and outcome of patients with Acquired Immunodefiency Syndrome-related Kaposi. Cancer 2003; 98:2440-2446.
11. Tam HK, Zhang ZF, Jacobson LP, Margolick JB, Chmiel JS, Rinaldo C, et al. Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma. Int J Cancer 2002; 98:916-922.
12. Krown SE, Testa MA, Huang J. AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 1997; 15:3085-3092.
13. Pellet C, Chevret S, Blum L, Gauville C, Hurault M, Blanchard G, et al. Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy. J Invest Dermatol 2001; 117:858-863.
14. Gill J, Bourboulia D, Wilkinson J, Hayes P, Cope A, Marcelin AG, et al. Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma-associated herpesvirus infection in patients with and without Kaposi sarcoma. J Acquir Immune Defic Syndr 2002; 31:384-390.
15. Bani-Sadr F, Fournier S, Molina JM. Relapse of Kaposi's sarcoma in HIV-infected patients switching from a protease inhibitor to a nonnucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy regimen. AIDS 2003; 17:1580-1581.
16. Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 1989; 7:1201-1207.
17. Cathomas G, Stalder A, McGandy CE, Mihatsch MJ. Distribution of human herpesvirus 8 DNA in tumorous and nontumorous tissue of patients with acquired immunodeficiency syndrome with and without Kaposi's sarcoma. Mod Pathol 1998; 11:415-420.
18. Zsikla V, Hailemariam S, Baumann M, Mund MT, Schaub N, Meier R, Cathomas G. Increased rate of Helicobacter pylori infection detected by PCR in biopsies with chronic gastritis. Am J Surg Pathol 2006; 30:242-248.
19. Polstra AM, Van den Burg R, Goudsmit J, Cornelissen M. Human herpesvirus 8 load in matched serum and plasma samples of patients with AIDS-associated Kaposi's sarcoma. J Clin Microbiol 2003; 41:5488-5491.
20. Campbell TB, Borok M, Gwanzura L, MaWhinney S, White IE, Ndemera B, et al. Relationship of human herpesvirus 8 peripheral blood virus and Kaposi's sarcoma clinical stage. AIDS 2000; 14:2282-2290.
21. Brown EE, Whitby D, Vitale F, Marshall V, Mbisa G, Gamache C, et al. Virologic, hematologic and immunologic risk factors for classic Kaposi sarcoma. Cancer 2006; 107:2109-2116.
22. Inoue N, Spira T, Lam L, Corhero JL, Luo W. Comparison of serologic responses between Kaposi' sarcoma-positive and -negative Men who were seropositive for both HHV8 and HIV. J Med Virol 2004; 74:202-206.
23. Lennette ET, Blackbourn DJ, Levy JA. Antibodies to human herpesvirus type 8 in the general population and in Kaposi's sarcoma patients. Lancet 1996; 348:858-861.
24. Quinlivan EB, Wang RX, Stewart PW, Kolmoltri C, Regamey N, Erb P, et al. Longitudinal sero-reactivity to human herpesvirus 8 (KSHV) in the Swiss HIV Cohort 4.7 years before KS. J Med Virol 2001; 64:157-166.
25. Jacobson LP, Jenkins FJ, Springer G, Munoz A, Shah KV, Phair J, et al. Interaction of human immunodeficiency virus type 1 and human herpesvirus type 8 infections on the incidence of Kaposi's sarcoma. J Infect Dis 2000; 181:1940-1949.
26. Stebbing J, Sanitt A, Nelson M, Powels T, Gazzard B, Bower M. A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy. Lancet 2006; 367:1495-1502.
27. Hengge UR, Ruzicka T, Tyring SK, Stuschke M, Roggendorf M, Schwartz RA, et al. Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 1: epidemiology, environmental predispositions, clinical manifestations, and therapy. Lancet Infect Dis 2002; 2:281-292.
28. Hengge UR, Ruzicka T, Tyring SK, Stuschke M, Roggendorf M, Schwartz RA, et al. Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma. Lancet Infect Dis 2002; 2:344-352.
29. Guihot A, Dupin N, Marcelin AG, Gorin I, Bedin AS, Bossi P, et al. Low T cell responses to human herpesvirus 8 in patients with AIDS-related and classic Kaposi sarcoma. J Infect Dis 2006; 194:1078-1088.